Table 4.
Variables Associated with Overall Survival (OS) in 70 Patients Diagnosed with NSCLC. Univariate and Multivariate Analyses Employing a Cox Proportional Hazards Model
| Clinicopathological Characteristics | Univariate Analysis | Multivariate Analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | HR | P value | HRc (95% CI) | P-value | |
| Age (yrs): ≤63 vs >63 | 0.33 (0.10–1.10) | −1.10 | 0.07 | ||
| Gender | |||||
| Male | 1.83 (0.54–6.14) | 0.60 | 0.32 | ||
| Smoke status | |||||
| Yes | 1.33 (0.33–5.36) | 0.28 | 0.68 | ||
| Histology | |||||
| ADC | 1.25 (0.32–4.86) | 0.22 | 0.74 | ||
| SqCC | 1.67 (0.33–8.37) | 0.51 | 0.53 | ||
| LCC (reference) | - | - | 0.82 | ||
| Clinical stage† | |||||
| I–II | 0.41 (0.11–1.52) | −0.87 | 0.18 | ||
| III–IV (reference) | - | - | - | ||
| Therapy | |||||
| Chemotherapy Yes |
0.36 (0.10–1.34) | −1.00 | 0.13 | ||
|
Relapse Yes |
8.47 (1.81–39.62) | 2.13 | 0.00 | 6.15 (1.03–36.44) | 0.04 |
| Immune checkpoint | |||||
| PD-L1+/mm2 | 1.00 (0.95–1.05) | 0.00 | 0.94 | ||
| polymorphisms in PD-L1 | |||||
| rs4742098 | |||||
| AA genotype | 2.02 (0.65–6.30) | 0.70 | 0.22 | ||
| G allele carrier (reference) | - | - | - | ||
| rs4143815 | |||||
| GG genotype | 1.58 (0.52–4.81) | 0.46 | 0.41 | ||
| C allele carrier (reference) | - | - | - | ||
| rs2297136 | |||||
| GG genotype | 1.24 (0.34–4.55) | 0.22 | 0.73 | ||
| A allele carrier (reference) | - | - | - | ||
| rs7041009 | |||||
| GG genotype | 0.20 (0.05–0.76) | −1.56 | 0.01 | 0.57 (0.12–2.70) | 0.48 |
| A allele carrier (reference) | - | - | - | ||
Notes: Bolded values are statically significant. †8th International Association for the Study of Lung Cancer [23].
Abbreviations: ADC, adenocarcinoma; SqCC, squamous cell carcinoma; LCC, large cell carcinoma; HR, hazard ratio (β coefficient); CI, confidence interval; PD-L1, programmed death-ligand 1.